[Molecular targeted therapies].
Current treatment paradigms in cancer patients are shifting from cytotoxic chemotherapies alone to single-agent and combination biological and targeted therapies. Targeted therapies are entering standard treatment paradigms. As patient responses to targeted therapies vary, predictive biomarkers will be an important tool of a patient's diagnostic workup in personalized medicine. This review provides a broad overview of molecular targeted agents, and highlight biomarkers, including novel adaptive clinical trial designs, incorporating putative biomarkers into prospective clinical trials.